Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
暂无分享,去创建一个
David M. Liebovitz | D. Boulware | D. Odde | J. Buse | J. Huling | C. Tignanelli | E. Wirtz | J. Thompson | N. Sherwood | K. Cohen | M. Puskarich | C. Bramante | H. Belani | T. Murray | M. Rose | B. Patel | J. Proper | N. Klatt | L. Siegel | K. Hartman | S. Fenno | S. Lindberg | M. Pullen | N. Bhat | J. Nicklas | B. Anderson | S. Erickson | A. Krager | G. Griffiths | K. Beckman
[1] Michael Lawrence Barnett,et al. Long-term Follow-up After Critical COVID-19: REMAP-CAP Revisited. , 2022, JAMA.
[2] A. Shukla,et al. Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. , 2022, The New England journal of medicine.
[3] James N. Druckman,et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults , 2022, JAMA network open.
[4] R. Chambers,et al. Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US , 2022, JAMA network open.
[5] G. Umpierrez,et al. Management of Hyperglycemia in Hospitalized, Non-Critically Ill Adults. , 2022, The New England journal of medicine.
[6] M. Morrone,et al. Long Covid: where we stand and challenges ahead , 2022, Cell Death & Differentiation.
[7] David M. Liebovitz,et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. , 2022, The New England journal of medicine.
[8] J. Rosmalen,et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study , 2022, The Lancet.
[9] S. Tebbutt,et al. A glimpse into long COVID and symptoms , 2022, The Lancet Respiratory Medicine.
[10] Claudia Ventura-López,et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial , 2022, Biomedicine & Pharmacotherapy.
[11] David M. Cutler. The Costs of Long COVID. , 2022, JAMA health forum.
[12] Kelsee Halpin,et al. Considering metformin as a second-line treatment for children and adolescents with prediabetes , 2022, Journal of pediatric endocrinology & metabolism : JPEM.
[13] K. Gersing,et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data , 2022, The Lancet Digital Health.
[14] Jun Yu,et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1 , 2022, Cell Death & Differentiation.
[15] L. Morin-Papunen,et al. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study , 2022, BMJ Open Diabetes Research & Care.
[16] Ian R. White,et al. Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: Clear guidance is needed , 2021, Contemporary clinical trials.
[17] D. Tandel,et al. Metformin suppresses SARS-CoV-2 in cell culture , 2021, bioRxiv.
[18] B. Lambrecht,et al. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial , 2021, The Lancet Respiratory Medicine.
[19] R. F. Campbell,et al. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses , 2021, JCI insight.
[20] G. Umpierrez,et al. Annals for Hospitalists Inpatient Notes - How We Treat Hyperglycemia in the Hospital , 2021, Annals of Internal Medicine.
[21] P. Canoll,et al. SARS-CoV-2 Infection Causes Dopaminergic Neuron Senescence , 2021, Research square.
[22] U. Topaloglu,et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information , 2021, medRxiv.
[23] B. Medhi,et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 , 2021, Annals of Internal Medicine.
[24] R. Platt,et al. Efficacy and Safety of Metformin for Obesity: A Systematic Review , 2021, Pediatrics.
[25] D. Odde,et al. mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses , 2020, Journal of medical virology.
[26] Richard A Parker,et al. Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification , 2020, Clinical trials.
[27] A. Haase,et al. Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets , 2020, bioRxiv.
[28] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[29] C. Seymour,et al. Association Between Preoperative Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes. , 2020, JAMA surgery.
[30] J. Manson,et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease , 2019, The New England journal of medicine.
[31] J. Manson,et al. Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer , 2019, The New England journal of medicine.
[32] A. Forslund,et al. Metformin in the Management of Childhood Obesity: A Randomized Control Trial. , 2018, Childhood obesity.
[33] A. Khalil,et al. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta‐analysis of randomized trials , 2018, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[34] S. Hyer,et al. Metformin in Pregnancy: Mechanisms and Clinical Applications , 2018, International journal of molecular sciences.
[35] Stuart J Pocock,et al. The Primary Outcome Fails - What Next? , 2016, The New England journal of medicine.
[36] K. Inaba,et al. Insulin-Treated Patients with Diabetes Mellitus Undergoing Emergency Abdominal Surgery Have Worse Outcomes than Patients Treated with Oral Agents , 2015, World Journal of Surgery.
[37] Silvio E. Inzucchi,et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. , 2014, JAMA.
[38] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.
[39] E. Salpeter,et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.